Odanacatib (MK-0822): A Comprehensive Review of a Potent Cathepsin K Inhibitor—From Blockbuster Efficacy to Discontinuation

Executive Summary

Odanacatib (MK-0822) represents one of the most compelling and cautionary case studies in modern pharmaceutical development. Developed by Merck & Co., this investigational small molecule was a highly potent and selective inhibitor of Cathepsin K, an enzyme central to osteoclastic bone resorption. Its mechanism of action was heralded as a significant advancement over existing osteoporosis therapies. Unlike traditional antiresorptive agents such as bisphosphonates, which suppress bone turnover by reducing the number and viability of osteoclasts, Odanacatib was designed to inhibit only the final enzymatic step of bone matrix degradation. This novel "formation-sparing" approach aimed to preserve osteoclast signaling to bone-forming osteoblasts, thereby uncoupling bone resorption from formation and tipping the remodeling balance toward a net gain in bone mass.

The clinical development program for Odanacatib yielded exceptionally strong efficacy data. In extensive Phase II studies and the pivotal, 16,000-patient Phase III Long-Term Odanacatib Fracture Trial (LOFT), the drug demonstrated robust, progressive increases in bone mineral density (BMD) over five years. More importantly, it achieved highly statistically significant reductions in the risk of vertebral, hip, and non-vertebral fractures. The anti-fracture efficacy was so profound that the LOFT trial's independent Data Monitoring Committee recommended its early termination in 2012, a rare event that signaled the arrival of a potential blockbuster therapy.

However, this promising trajectory was ultimately derailed by the emergence of critical safety signals. While the overall incidence of adverse events was generally balanced, pre-specified analyses of the long-term data revealed a small but statistically significant increase in the risk of stroke. This finding, confirmed by an independent adjudication committee, proved to be an insurmountable hurdle. For a drug intended for chronic, preventative use in a largely elderly population with pre-existing cardiovascular risk factors, the benefit of fracture reduction could not outweigh the risk of a devastating cerebrovascular event. In September 2016, Merck announced the discontinuation of the Odanacatib development program. This report provides an exhaustive analysis of Odanacatib, detailing its chemical properties, its unique mechanism of action, the full scope of its clinical pharmacology and efficacy, and a critical post-mortem of the safety data that led to its withdrawal, positioning it within the broader landscape of osteoporosis treatment.

Odanacatib: A Profile of a Novel Cathepsin K Inhibitor

1.1. Identification and Chemical Characteristics

Odanacatib is an investigational small molecule drug developed by Merck & Co., identified by the codename MK-0822.[1] As a distinct chemical entity, it is registered under the Chemical Abstracts Service (CAS) Number 603139-19-1 and cataloged in major pharmacological databases with identifiers such as DrugBank ID DB06670 and Unique Ingredient Identifier (UNII) N673F6W2VH.[1]

The molecular structure of Odanacatib is defined by the chemical formula C25​H27​F4​N3​O3​S, corresponding to an average molecular weight of 525.56 g/mol and a precise monoisotopic mass of 525.170925567 Da.[1] Its systematic International Union of Pure and Applied Chemistry (IUPAC) name is (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-ethyl]amino]pentanamide.[3] Physically, Odanacatib is a solid compound with poor aqueous solubility, being practically insoluble in water and ethanol. It demonstrates solubility in organic solvents such as dimethyl sulfoxide (DMSO) and slight solubility in methanol and chloroform.[5] This lipophilic character and low aqueous solubility are fundamental physicochemical properties that significantly influence its pharmacokinetic profile, particularly its absorption.

The chemical design of Odanacatib as a neutral, non-basic biaryl compound was a critical and deliberate evolution in the development of Cathepsin K inhibitors.[8] Earlier drug candidates in this class, such as balicatib, were basic molecules. This chemical property caused them to become trapped and accumulate within the acidic environment of cellular lysosomes, the primary site of action for many cathepsin enzymes. This lysosomotropic behavior was hypothesized to lead to a loss of selectivity and off-target inhibition of other cathepsins (e.g., Cathepsin B, L, and S) that are active in these organelles, potentially causing adverse effects like the morphea-like skin lesions that led to balicatib's discontinuation.[8] By engineering Odanacatib as a neutral molecule, developers aimed to prevent this lysosomal accumulation, thereby enhancing its selectivity for Cathepsin K and improving the overall safety profile of the drug class. This molecular design strategy represents a key aspect of its development history and the scientific rationale underpinning its advancement into late-stage clinical trials.

Table 1: Key Chemical and Physical Properties of Odanacatib

Property	Value
DrugBank ID	DB06670 1
CAS Number	603139-19-1 2
UNII	N673F6W2VH 2
Type	Small Molecule 1
IUPAC Name	(2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-ethyl]amino]pentanamide 3
Chemical Formula	C25​H27​F4​N3​O3​S 1
Average Mass	525.56 g/mol 1
Monoisotopic Mass	525.170925567 Da 1
Solubility	Insoluble in water and ethanol; Soluble in DMSO; Slightly soluble in methanol and chloroform 6

1.2. The Therapeutic Target: Cathepsin K in Bone Remodeling

The therapeutic rationale for Odanacatib is rooted in the specific and critical role of its target, Cathepsin K (CatK), in the process of bone remodeling. Bone remodeling is a continuous physiological process involving the removal of old bone by osteoclasts (resorption) and the deposition of new bone by osteoblasts (formation).[12] In pathological conditions like postmenopausal osteoporosis, this process becomes unbalanced, with the rate of resorption exceeding formation, leading to a net loss of bone mass, microarchitectural deterioration, and increased fracture risk.[13]

CatK is a lysosomal cysteine protease that is expressed predominantly in osteoclasts.[1] It functions as the primary collagenase responsible for the degradation of the organic component of the bone matrix, which is approximately 90% type I collagen.[12] The process of osteoclastic bone resorption is sequential. First, the osteoclast attaches to the bone surface and creates a sealed, acidic microenvironment (pH ~5) via vacuolar proton pumps. This acidic milieu dissolves the inorganic mineral component (hydroxyapatite) of the bone. Second, the demineralized organic matrix is exposed, allowing CatK, which is secreted into this resorption lacuna and is optimally active at low pH, to cleave and digest the collagen fibrils.[12]

The selection of CatK as a therapeutic target for osteoporosis was exceptionally well-founded, supported by two strong pillars of evidence: high tissue specificity and direct human genetic validation. The predominant expression of CatK in osteoclasts suggested that a selective inhibitor would have a focused effect on the skeleton with minimal potential for on-target toxicity in other tissues.[6] This targeted approach is highly desirable in drug development. Furthermore, the pivotal role of CatK in bone biology is unequivocally demonstrated by the rare autosomal recessive genetic disorder, pycnodysostosis.[8] This condition, caused by a loss-of-function mutation in the gene encoding CatK, results in a high bone mass phenotype characterized by osteosclerosis. This human "knockout" model provided powerful genetic proof-of-concept that inhibiting CatK activity would lead to an increase in bone mass. Together, these factors made CatK one of the most attractive and rationally chosen targets for the development of a novel anti-osteoporosis therapy, fueling the significant scientific and commercial interest in Odanacatib and the broader class of CatK inhibitors.

Mechanism of Action: Targeting Bone Resorption with Osteoclast Preservation

The mechanism of action of Odanacatib represented a significant departure from all existing antiresorptive therapies for osteoporosis. Its therapeutic effect was derived from the potent and highly selective inhibition of Cathepsin K, which, in turn, was hypothesized to produce a unique "uncoupling" of bone resorption and formation by preserving the viability and signaling functions of osteoclasts.

2.1. Potent and Selective Inhibition of Cathepsin K

Odanacatib is a potent, selective, and reversible non-covalent inhibitor of the human Cathepsin K enzyme.[15] In vitro biochemical assays have established its high potency, with a reported half-maximal inhibitory concentration (

IC50​) of 0.2 nM for human CatK.[6] The mechanism of inhibition is believed to involve the binding of the Odanacatib molecule to the active site of the enzyme, thereby blocking its proteolytic activity on its primary substrate, type I collagen.[1]

A crucial feature of Odanacatib is its high degree of selectivity for CatK over other members of the cathepsin family. This selectivity was a key design objective to minimize off-target effects. Odanacatib is reported to be approximately 300-fold more selective for CatK than for Cathepsin S, over 1000-fold more selective than for Cathepsin B, and nearly 3000-fold more selective than for Cathepsin L.[5] This selectivity profile, combined with its neutral chemical nature designed to prevent non-specific accumulation in lysosomes, was intended to confer a superior safety profile compared to earlier, less selective CatK inhibitors that had failed in development due to adverse events such as skin lesions.[8]

2.2. The "Uncoupling" Hypothesis: A Formation-Sparing Antiresorptive Agent

The central and most innovative aspect of Odanacatib's mechanism is its proposed ability to function as a "formation-sparing" antiresorptive agent.[15] This concept fundamentally differs from the action of traditional antiresorptive drugs like bisphosphonates and denosumab. These established therapies reduce bone resorption primarily by decreasing the number and/or survival of osteoclasts.[16] A direct consequence of this is a secondary, tightly coupled reduction in bone formation, as the signaling from active osteoclasts to bone-forming osteoblasts is diminished. This leads to an overall suppression of bone turnover.[8]

Odanacatib was designed to circumvent this coupling. By selectively inhibiting only the final enzymatic function of the osteoclast—the degradation of the collagen matrix—it was hypothesized to leave the osteoclast cell otherwise intact and viable.[16] These living but non-resorbing osteoclasts could, in theory, continue to secrete the paracrine factors that recruit and stimulate osteoblasts to form new bone. This would effectively "uncouple" resorption from formation, leading to a powerful suppression of bone breakdown while bone formation is relatively preserved.[12]

This hypothesis was supported by compelling evidence from both preclinical and clinical studies. In animal models, Odanacatib treatment did not reduce osteoclast numbers.[16] Most strikingly, in studies on ovariectomized (OVX) monkeys, Odanacatib not only suppressed bone resorption markers but also uniquely stimulated bone formation on the periosteal (outer) surface of the femoral neck, resulting in a measurable increase in cortical thickness.[17] This suggested a potential anabolic-like effect in specific bone compartments, a feature entirely absent in other antiresorptive agents. In clinical trials, this mechanism was corroborated by biomarker data showing a profound reduction in bone resorption markers with only a modest and transient decrease in bone formation markers.[8] Furthermore, bone biopsy studies and analysis of serum TRAP5b (a biomarker of osteoclast number) in patients treated with Odanacatib confirmed that osteoclast viability was maintained during therapy.[8] This unique mechanism positioned Odanacatib as a potentially superior long-term therapy, capable of producing a more favorable net balance of bone remodeling compared to simply slowing down the entire process.

2.3. Mechanistic Differentiation from Bisphosphonates and RANKL Inhibitors

The distinct mechanism of Odanacatib becomes clearer when contrasted with the two major classes of antiresorptive drugs.

• Bisphosphonates (e.g., Alendronate): These drugs bind to the mineral component of bone and are taken up by osteoclasts during resorption. Inside the osteoclast, they disrupt intracellular pathways, ultimately inducing apoptosis (programmed cell death).[16] This reduction in the osteoclast population leads to decreased bone resorption and, consequently, a secondary decrease in bone formation. Because bisphosphonates are incorporated into the bone matrix, their effects are long-lasting even after treatment discontinuation.[21]
• RANKL Inhibitors (e.g., Denosumab): Denosumab is a monoclonal antibody that binds to and neutralizes RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand), a key cytokine required for the formation, function, and survival of osteoclasts.[12] By preventing RANKL from binding to its receptor (RANK) on osteoclast precursors and mature osteoclasts, denosumab potently inhibits osteoclastogenesis and increases osteoclast apoptosis, leading to a profound suppression of bone resorption and a coupled decrease in bone formation.[25]

In stark contrast, Odanacatib does not interfere with osteoclast formation or survival; it only blocks the function of a single enzyme, CatK.[13] This mechanistic difference has a critical consequence: reversibility. Upon discontinuation of Odanacatib, the enzymatic inhibition ceases, and the large pool of viable osteoclasts can resume resorption activity. This leads to a rapid increase in bone turnover markers and a reversal of the gains in BMD, with bone density returning to near-baseline levels within one to two years.[8] This rapid offset of effect is fundamentally different from the prolonged action of bisphosphonates and presents both potential advantages (e.g., easier management of side effects) and disadvantages (e.g., need for continuous adherence).

Clinical Pharmacology: A Comprehensive Review of ADME and Pharmacodynamic Effects

The clinical pharmacology of Odanacatib is characterized by a pharmacokinetic profile that enables a convenient once-weekly dosing regimen and a pharmacodynamic profile that clearly demonstrates potent and selective target engagement. The interplay between its absorption, distribution, metabolism, excretion (ADME), and its effects on bone turnover markers provides a complete picture of the drug's behavior in the human body.

4.1. Pharmacokinetic Profile: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic properties of Odanacatib define it as a low-solubility, low-clearance compound with a long elimination half-life, features that were both advantageous and challenging for its clinical development.

• Absorption: Following oral administration, Odanacatib is absorbed with a variable time to maximum plasma concentration (Tmax​), typically ranging from 2 to 8 hours.[1] Its absorption is limited by its poor aqueous solubility, which results in less than dose-proportional increases in systemic exposure, particularly at doses above 10 mg.[15] This is reflected in its absolute bioavailability, which decreases as the dose increases; for instance, bioavailability is approximately 70% for a 30 mg dose but falls to 30% for a 50 mg dose in the fasted state.[1] The drug's lipophilic nature means that its absorption is significantly influenced by food. Administration with a high-fat meal can increase the bioavailability of a 50 mg dose to 49% and nearly double the overall exposure (AUC), while also delaying Tmax​ to around 10.5 hours.[1] This food effect underscores the solubility-limited absorption and introduces a potential source of inter-patient variability in drug exposure.
• Distribution: Once absorbed into the systemic circulation, Odanacatib is extensively bound to plasma proteins, with a bound fraction of approximately 97.5%.[1] It has a moderate volume of distribution ( Vd​) of about 100 L, which is greater than total body water, indicating that the drug distributes from the plasma into tissues.[1]
• Metabolism: Odanacatib is eliminated primarily through metabolism, which accounts for approximately 70% of its clearance.[15] The metabolism is mediated predominantly by the cytochrome P450 enzyme CYP3A4, with a minor contribution from CYP2C8.[1] The main metabolic pathway is hydroxylation of the fluoroleucine moiety, which produces an active metabolite (M6). However, this metabolite is approximately 25 times less potent in inhibiting CatK than the parent Odanacatib molecule and does not circulate at detectable levels, suggesting it contributes minimally to the overall pharmacological effect.[1] Other minor metabolic pathways include glucuronidation, oxidation, hydrolysis, and dealkylation.[1] As a substrate of CYP3A4 and the efflux transporter P-glycoprotein, Odanacatib has a significant potential for drug-drug interactions with inhibitors or inducers of these pathways.[1]
• Excretion: The most defining pharmacokinetic feature of Odanacatib is its slow elimination, characterized by a long apparent terminal half-life (t1/2​) that ranges from 66 to 95 hours across various studies.[3] This long half-life is a direct result of its low systemic clearance of approximately 0.8 L/h.[3] This favorable pharmacokinetic property is what allows for sustained drug concentrations throughout the week, making a convenient once-weekly oral dosing regimen clinically viable. The primary route of excretion is via the feces, which accounts for about 74.5% of an administered dose, largely as unchanged parent drug.[3] A smaller fraction, approximately 16.9%, is excreted in the urine, primarily in the form of metabolites.[3]

Table 2: Summary of Odanacatib Pharmacokinetic (ADME) Parameters

Parameter	Value / Description
Administration Route	Oral 3
Bioavailability	Dose-dependent and solubility-limited; ~70% at 30 mg, ~30% at 50 mg (fasted); Increases to 49% (50 mg) with a high-fat meal 1
Tmax​ (Time to Peak Concentration)	2–8 hours (fasted); delayed to ~10.5 hours with a high-fat meal 1
Plasma Protein Binding	~97.5% 1
Volume of Distribution (Vd​)	~100 L 1
Metabolism	Primarily hepatic via CYP3A4 and CYP2C8; major pathway is hydroxylation 1
Apparent Terminal Half-life (t1/2​)	85–95 hours (harmonic mean ~84.8 h) 3
Systemic Clearance	Low; ~0.8 L/h 3
Primary Route of Excretion	Feces (~75%, mostly as unchanged drug); Urine (~17%, mostly as metabolites) 3

4.2. Pharmacodynamic Profile: Impact on Bone Turnover Markers

The pharmacodynamic effects of Odanacatib provide direct clinical evidence of its mechanism of action, demonstrating a potent and differential impact on markers of bone resorption and formation.

• Bone Resorption Markers: Odanacatib treatment leads to a rapid, profound, and sustained dose-dependent reduction in biochemical markers of bone resorption. Within 24 hours of a single 50 mg dose, a significant decrease is observed.[27] With the once-weekly 50 mg regimen used in late-stage trials, this suppression is maintained throughout the dosing interval. Studies consistently report reductions of approximately 60–70% in serum C-telopeptides of type I collagen (sCTx) and 50–78% in the urinary N-telopeptides of type I collagen to creatinine ratio (uNTx/Cr).[15] This robust suppression of resorption markers confirms potent and continuous engagement of the Cathepsin K target.
• Bone Formation Markers: The effect of Odanacatib on markers of bone formation, such as bone-specific alkaline phosphatase (BSAP) and serum N-terminal propeptide of type I collagen (P1NP), is markedly different and provides the clinical evidence for its "formation-sparing" properties. In contrast to the deep suppression of resorption markers, formation markers show only a modest and transient decrease. Typically, an initial reduction of about 15–35% is seen in the first year of treatment.[17] However, with continued therapy over two to four years, these markers tend to gradually return toward pre-treatment baseline levels, even as resorption remains deeply suppressed.[8] This divergence in the response of resorption and formation markers is the key pharmacodynamic signature of Odanacatib, distinguishing it from other antiresorptive agents that cause a more parallel and sustained decline in both processes.
• Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship: The link between drug concentration and biological effect has been formally modeled. The relationship between plasma Odanacatib concentration and the suppression of the uNTx/Cr resorption marker was well-characterized, yielding a modeled half-maximal effective concentration (EC50​) of 43.8 nM and a maximal achievable reduction (Emax​) of approximately 80%.[27] This modeling confirms that the therapeutic doses selected for clinical trials were sufficient to achieve near-maximal suppression of bone resorption.

The Clinical Development Pathway: From Preclinical Promise to Phase III Efficacy

The clinical development of Odanacatib was a multi-stage journey that progressively built a compelling case for its efficacy. Starting with foundational early-phase studies that established its pharmacological profile, the program advanced through extensive Phase II trials that demonstrated its ability to build bone density over the long term, culminating in a landmark Phase III trial that provided definitive evidence of its potent anti-fracture efficacy.

5.1. Early Phase Development and Dose Selection

Phase I clinical trials were conducted in healthy volunteers and the target population of postmenopausal women to establish the initial safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profile of Odanacatib.[4] These studies evaluated a range of single and multiple oral doses. The key findings from this early stage were the confirmation of Odanacatib's long elimination half-life and its ability to produce a sustained suppression of bone resorption biomarkers over a seven-day period.[11] This pharmacokinetic and pharmacodynamic evidence provided the crucial support for advancing a convenient once-weekly dosing regimen into further development.

Following the Phase I program, a large Phase IIb dose-ranging study was initiated to identify the optimal dose for long-term treatment. This trial evaluated several weekly doses (including 5, 25, and 50 mg) against placebo in postmenopausal women with low bone mineral density.[22] After 12 months of treatment, the results showed a clear dose-dependent increase in BMD and suppression of bone turnover markers. Based on the analysis of these data, the 50 mg once-weekly dose was selected as the optimal regimen for the pivotal Phase III program, as it provided a robust effect on BMD with a favorable safety and tolerability profile.[8]

5.2. Phase II Findings: Sustained Increases in Bone Mineral Density (BMD)

The Phase IIb study and its subsequent long-term extension phases provided powerful evidence of Odanacatib's ability to progressively increase bone mass over several years. This was a critical finding, as it demonstrated that the drug's effect did not plateau and that it could continue to strengthen the skeleton with prolonged use.[8]

After five years of continuous treatment with the 50 mg weekly dose, participants showed substantial and clinically meaningful increases in BMD from their baseline values. At the lumbar spine, BMD increased by an average of 11.9%, while at the total hip, the increase was 8.5%. Similar impressive gains were seen at the femoral neck (+9.8%) and hip trochanter (+10.9%).[22] These long-term increases in bone density are comparable to those achieved with the most potent injectable antiresorptive therapies, such as zoledronic acid and denosumab, highlighting the powerful effect of Odanacatib.[32]

Furthermore, a separate Phase II study was conducted to evaluate Odanacatib's efficacy in a clinically relevant scenario: as a sequential therapy for women who had already undergone long-term treatment with the bisphosphonate alendronate. This 24-month, placebo-controlled trial demonstrated that switching to Odanacatib after three or more years of alendronate therapy resulted in significant additional gains in BMD at the lumbar spine and all hip sites compared to switching to placebo.[21] This finding suggested that Odanacatib could be a valuable option for patients requiring continued treatment after a course of bisphosphonates, further broadening its potential clinical utility.

5.3. The LOFT Trial: Demonstrating Robust Anti-Fracture Efficacy

The definitive test of any osteoporosis therapy is its ability to prevent fractures. The Long-Term Odanacatib Fracture Trial (LOFT) was designed to provide this evidence on a massive scale. LOFT was a multinational, randomized, double-blind, placebo-controlled, event-driven trial that enrolled 16,713 postmenopausal women aged 65 years or older with established osteoporosis.[8] Participants were randomized to receive either Odanacatib 50 mg once weekly or a matching placebo, with all participants receiving supplemental calcium and vitamin D.

The trial's design was event-driven, meaning it was planned to continue until a pre-specified number of hip fracture events had occurred. However, in July 2012, the study's independent Data Monitoring Committee (DMC) conducted a planned interim analysis of the data. The results were so compelling that the DMC recommended the study be stopped early due to "robust efficacy and a favorable benefit-risk profile".[8] Such a recommendation is uncommon and signifies a very large and clear treatment benefit, making it ethically challenging to continue withholding the effective therapy from the placebo group.

The final efficacy analysis from the LOFT trial confirmed these initial findings, showing highly statistically significant reductions in the risk of all major types of osteoporotic fractures. Compared to patients receiving placebo, those treated with Odanacatib experienced profound relative risk reductions across the primary endpoints [10]:

• A 54% reduction in new or worsening radiographically-assessed (morphometric) vertebral fractures.
• A 47% reduction in clinical hip fractures.
• A 23% reduction in clinical non-vertebral fractures.
• A 72% reduction in clinical vertebral fractures.

These anti-fracture efficacy results were accompanied by continued, progressive increases in BMD. Over the five-year duration of the study, the difference in BMD gain between the Odanacatib and placebo groups was 11.2% at the lumbar spine and 9.5% at the total hip, with all fracture and BMD outcomes achieving a p-value of <0.001.[10] The strength and consistency of these results across multiple skeletal sites and fracture types positioned Odanacatib as one of the most effective osteoporosis treatments ever developed, validating its novel mechanism of action and cementing its status as a potential blockbuster drug.

Table 3: Summary of Efficacy Outcomes from the Phase III LOFT Trial

Fracture Type	Odanacatib Group (Incidence %)	Placebo Group (Incidence %)	Relative Risk Reduction (%)	p-value
Morphometric Vertebral	3.7% 39	7.8% 39	54% 14	<0.001 14
Clinical Hip	0.8% 39	1.6% 39	47% 14	<0.001 14
Clinical Non-Vertebral	5.1% 39	6.7% 39	23% 14	<0.001 14
Clinical Vertebral	Not explicitly reported	Not explicitly reported	72% 14	<0.001 14

The Unraveling of a Promising Candidate: A Detailed Analysis of the Odanacatib Safety Profile

Despite the unequivocally positive efficacy data, the ultimate fate of Odanacatib was sealed by its safety profile. A meticulous, long-term evaluation of adverse events in the LOFT trial and its extension revealed a pattern of risk that, while small in absolute terms, was significant enough to render the drug's overall benefit-risk profile unfavorable for a chronic, preventative therapy. The analysis of these safety signals, particularly the increased risk of stroke, provides a critical lesson in pharmacovigilance.

6.1. Overview of the Safety and Tolerability Data

Across the extensive clinical program, Odanacatib was generally well-tolerated. In the pivotal LOFT trial, the overall incidence of adverse events (AEs) and serious adverse events (SAEs) was comparable between the Odanacatib and placebo groups.[14] However, the study protocol included a pre-specified list of adverse events of special interest that were subject to formal adjudication by an independent committee. This list was based on theoretical concerns, known risks of other osteoporosis drugs, and adverse events seen with earlier CatK inhibitors. It was within this adjudicated analysis that concerning imbalances began to emerge.[10]

6.2. The Critical Signal: Adjudicated Stroke Risk Analysis

The single most important finding that led to the termination of the Odanacatib program was the identification of an increased risk of stroke. An initial numeric imbalance in adjudicated stroke events was noted at the time the LOFT trial was stopped early for efficacy in 2012.[13] Recognizing the potential seriousness of this signal, Merck initiated a blinded extension of the trial to allow for the collection of additional long-term safety data, a crucial step in clarifying the risk.[13]

The final, comprehensive analysis of the combined data from the base LOFT trial and its extension study was conducted by an independent academic research organization, the Thrombolysis in Myocardial Infarction (TIMI) Study Group, to ensure objectivity.[38] This analysis confirmed the initial concern. The cumulative incidence of adjudicated stroke was found to be 2.3% (187 events in 8043 patients) in the Odanacatib group, compared to 1.7% (137 events in 8028 patients) in the placebo group.[38] This difference translated into a statistically significant 37% increase in the relative risk of stroke, with a Hazard Ratio (HR) of 1.37 (95% Confidence Interval [CI], 1.10–1.71; p=0.005).[38] Further analysis revealed that the excess strokes were almost entirely ischemic in nature, rather than hemorrhagic.[38] This confirmed, statistically robust finding of an increased risk for a severe and potentially fatal adverse event was the primary and definitive reason for the discontinuation of the drug's development in September 2016.[2] The mechanistic basis for this increased stroke risk remains unknown and is particularly puzzling given that some preclinical data had suggested that CatK inhibition might be protective against atherosclerosis.[38]

6.3. Adverse Events of Special Interest: Morphea-Like Skin Lesions and Atypical Femoral Fractures

Beyond the stroke signal, the adjudicated analysis also confirmed imbalances in two other adverse events of special interest.

• Morphea-Like Skin Lesions: These localized, scleroderma-like skin lesions were a known concern for the CatK inhibitor class, having been a primary reason for the discontinuation of an earlier candidate, balicatib.[9] In the LOFT trial, these lesions occurred more frequently in patients receiving Odanacatib, with 12 to 13 adjudicated cases (an incidence of 0.1–0.2%) compared to only 3 cases (<0.1%) in the placebo group.[10] While the incidence was low, the imbalance was clear. A mitigating factor was that in most cases, the skin lesions were reported to resolve or improve after the discontinuation of the study drug.[10]
• Atypical Femoral Fractures (AFFs): AFFs are rare stress fractures of the subtrochanteric femur, a known, albeit infrequent, complication of long-term therapy with potent antiresorptive agents like bisphosphonates and denosumab. The LOFT trial found that these fractures also occurred more often with Odanacatib. There were 5 to 10 adjudicated cases (an incidence of ~0.1%) in the Odanacatib group, whereas no cases were reported in the placebo group.[10] Investigators noted that these fractures differed somewhat from classic bisphosphonate-associated AFFs, as they tended to occur in patients with very severe underlying osteoporosis and were often associated with some degree of trauma, rather than being spontaneous.[10] Nevertheless, the imbalance raised concerns that Odanacatib, despite its formation-sparing mechanism, might still share this rare but serious skeletal side effect with other potent antiresorptives.

6.4. Evaluation of Other Cardiovascular and Serious Adverse Events

The independent adjudication committee also evaluated other cardiovascular outcomes.

• Major Adverse Cardiovascular Events (MACE): The composite endpoint of MACE, defined as cardiovascular death, myocardial infarction, or stroke, showed a numeric trend toward a higher incidence in the Odanacatib group. The final analysis yielded a hazard ratio of 1.17, but the confidence interval crossed 1.0, indicating that this trend did not reach statistical significance.[38]
• Atrial Fibrillation/Flutter: A similar non-significant trend was observed for new-onset atrial fibrillation or flutter, with a hazard ratio of 1.22 (p=0.06).[14]
• Mortality: There was a small, non-significant numeric imbalance in all-cause mortality, with a hazard ratio of 1.13.[14]
• Osteonecrosis of the Jaw (ONJ): On a positive note, the trial confirmed no adjudicated cases of ONJ in either treatment group.[10] The absence of this rare but serious adverse event, which is a known risk with bisphosphonates and denosumab, was a notable point of differentiation in Odanacatib's safety profile.

Table 4: Adjudicated Adverse Events of Special Interest in the LOFT Trial and Extension (Odanacatib vs. Placebo)

Adverse Event	Odanacatib (n, Incidence %)	Placebo (n, Incidence %)	Hazard Ratio (95% CI)	p-value
Stroke	187 (2.3%) 39	137 (1.7%) 39	1.37 (1.10–1.71) 38	0.005 38
MACE (Composite)	401 (5.0%) 39	343 (4.3%) 39	1.17 (0.93–1.36) 14	Not Significant 38
Atrial Fibrillation/Flutter	112 (1.4%) 39	96 (1.2%) 39	1.22 (0.99–1.50) 38	0.06 38
All-Cause Mortality	401 (5.0%) 39	356 (4.4%) 39	1.13 (0.95–1.35) 14	Not Significant 10
Atypical Femoral Fractures	5–10 (~0.1%) 10	0 (0.0%) 14	Not Applicable	Not Applicable
Morphea-like Skin Lesions	12–13 (0.1–0.2%) 10	3 (<0.1%) 14	Not Applicable	Not Applicable
Osteonecrosis of the Jaw	0 (0.0%) 14	0 (0.0%) 14	Not Applicable	Not Applicable

The Discontinuation Decision: Synthesizing the Final Benefit-Risk Profile

The decision by Merck & Co. to terminate the development of Odanacatib in 2016 was the culmination of a careful, multi-year process of weighing the drug's profound efficacy against a newly confirmed and serious safety risk. This final benefit-risk assessment serves as a quintessential example of the rigorous standards applied to therapies for chronic, non-life-threatening conditions, where the tolerance for iatrogenic harm is exceptionally low.

7.1. Weighing Robust Efficacy Against Unacceptable Risk

The central dilemma for Odanacatib was the juxtaposition of its two definitive clinical outcomes: a powerful, clinically meaningful reduction in debilitating fractures versus a small but statistically significant increase in the risk of stroke. The efficacy data were unambiguous. The LOFT trial had demonstrated that Odanacatib could prevent a large number of vertebral and hip fractures, outcomes that are associated with significant morbidity, mortality, and healthcare costs.[14] This represented a substantial and undeniable clinical benefit.

However, the risk of stroke is of a different magnitude. As a preventative therapy intended for long-term use in millions of elderly individuals, many of whom already possess baseline risk factors for cardiovascular disease, any treatment-emergent increase in stroke risk is a major concern.[10] While the absolute increase in risk was modest—an excess of approximately 6 strokes per 1000 patients treated over the study's duration—the relative risk was significantly elevated by 37%.[38] For regulators, clinicians, and patients, the calculus becomes a difficult one: is the prevention of a certain number of fractures an acceptable trade-off for causing a smaller, but still significant, number of potentially fatal or permanently disabling strokes?

For a chronic, non-malignant disease like osteoporosis, the principle of "first, do no harm" (primum non nocere) is paramount. The official statements from Merck made it clear that this principle guided their final decision. Dr. Roger M. Perlmutter, then president of Merck Research Laboratories, articulated the conclusion succinctly: "We are disappointed that the overall benefit-risk profile for odanacatib does not support filing or further development... We have learned that odanacatib treatment reduces the risk of osteoporotic fractures. At the same time, we believe that the increased risk of stroke in our Phase 3 trial does not support further development".[35] This statement encapsulates the final judgment that the established benefit, however large, could not justify the introduction of a new, serious iatrogenic risk into the patient population.

7.2. The End of the Development Program

The timeline of Odanacatib's final years illustrates the gradual and evidence-based nature of the decision-making process. The initial euphoria following the 2012 announcement of the LOFT trial's early termination for efficacy was soon tempered by the acknowledgment of remaining safety questions.[9] This led to announced delays in the planned regulatory filings in 2013 and 2014, as Merck committed to collecting the necessary long-term data from the blinded trial extension to fully characterize the cardiovascular risk profile.[9] This period of extended data collection and independent analysis was a demonstration of responsible pharmacovigilance.

The final announcement in September 2016, confirming the discontinuation of the entire program, marked the definitive end of Odanacatib's journey.[40] This outcome had significant repercussions for the field of osteoporosis treatment. It dealt a major blow to the entire Cathepsin K inhibitor drug class, which had already seen other candidates, such as balicatib (discontinued for skin lesions) and ONO-5334 (discontinued for commercial reasons), fail to reach the market.[9] The failure of Odanacatib, the most advanced and promising candidate, raised fundamental questions about the safety of targeting Cathepsin K. It remains an unresolved issue whether the observed stroke risk was an idiosyncratic, off-target effect of the Odanacatib molecule itself, or a more concerning on-target, class-wide effect of inhibiting CatK in extra-skeletal tissues like the vasculature.[9] This lingering uncertainty has cast a long shadow over future research and development in this area.

Odanacatib in the Osteoporosis Treatment Landscape: A Comparative Perspective

To fully appreciate the significance of Odanacatib's development and subsequent failure, it is essential to position it within the context of the existing therapeutic landscape for osteoporosis. Odanacatib was not designed to be an incremental improvement; its unique profile aimed to address the perceived limitations of established drug classes, including antiresorptive agents (bisphosphonates, RANKL inhibitors) and anabolic agents (parathyroid hormone analogues).

8.1. Comparison with Antiresorptive Agents (Alendronate, Denosumab)

• Mechanism: Odanacatib's "formation-sparing" mechanism was its key point of differentiation. While alendronate (a representative bisphosphonate) and denosumab potently inhibit bone resorption, they do so by reducing osteoclast number and viability, which leads to a coupled suppression of bone formation.[16] Odanacatib's ability to preserve bone formation was seen as a potential advantage for long-term skeletal health, possibly avoiding the state of very low bone turnover that has been linked to rare side effects like AFFs.[10]
• Efficacy: In terms of anti-fracture efficacy and the magnitude of BMD gains, Odanacatib demonstrated performance that was highly competitive with the most potent antiresorptives. Its 47% reduction in hip fracture risk and 11.2% increase in lumbar spine BMD over five years are comparable to results seen with denosumab and intravenous zoledronic acid, and generally superior to oral bisphosphonates like alendronate.[14] Furthermore, its proven efficacy in patients previously treated with alendronate positioned it as an excellent second-line or sequential therapy option.[21]
• Safety: The safety profiles present a complex trade-off. Odanacatib's fatal flaw was the increased risk of stroke, an adverse event not associated with bisphosphonates or denosumab.[38] It also carried a higher risk of morphea-like skin lesions.[14] Conversely, Odanacatib appeared to have no risk of ONJ, a known concern for both bisphosphonates and denosumab.[14] Both Odanacatib and the other potent antiresorptives were associated with an increased risk of AFFs, suggesting this may be a consequence of profound resorption inhibition regardless of the mechanism.[10]
• Dosing and Reversibility: Odanacatib offered the convenience of a once-weekly oral tablet, which is often preferred by patients over the strict dosing requirements of oral bisphosphonates (e.g., fasting, remaining upright) or the need for injections with denosumab.[8] Its effects were also rapidly reversible upon discontinuation, unlike the prolonged skeletal retention of bisphosphonates.[8] While this reversibility could be an advantage, it also contrasts with denosumab, where rapid reversibility is associated with a rebound increase in bone turnover and a risk of multiple vertebral fractures, a phenomenon not fully characterized for Odanacatib.

8.2. Comparison with Anabolic Agents (Teriparatide)

• Mechanism: The comparison with anabolic agents like teriparatide highlights a different mechanistic distinction. Teriparatide, a recombinant fragment of parathyroid hormone, is a true bone-building agent that directly stimulates osteoblast activity, leading to a powerful increase in bone formation that outweighs its stimulation of resorption.[12] Odanacatib, while "formation-sparing," is fundamentally an antiresorptive agent; it prevents bone loss rather than actively building new bone de novo.
• Efficacy: Anabolic agents typically produce larger and faster increases in lumbar spine BMD compared to any antiresorptive drug, including Odanacatib.[47] However, their effect on cortical bone and hip BMD can be less pronounced. The unique preclinical finding that Odanacatib increased cortical thickness in the femoral neck suggested it might have offered a distinct pattern of skeletal benefit.[17]
• Safety: The safety profiles are entirely different. Teriparatide is associated with potential side effects such as hypercalcemia, dizziness, and nausea, and its use is limited to two years due to a theoretical risk of osteosarcoma observed in rodent studies.[45] Its cardiovascular safety profile is generally considered favorable, with no signals for stroke or MACE.[50] This stands in stark contrast to Odanacatib's primary safety liability.
• Place in Therapy: Due to their cost and need for daily subcutaneous injection, anabolic agents are typically reserved for patients with severe osteoporosis who are at a very high risk of fracture.[49] Odanacatib was positioned for much broader use, as a first- or second-line oral therapy for the general population of postmenopausal women with osteoporosis, a significantly larger market segment.

Ultimately, Odanacatib was designed to occupy a highly attractive and potentially lucrative therapeutic niche. It aimed to combine the oral convenience of bisphosphonates, the potent efficacy of injectable biologics like denosumab, and a novel, theoretically superior mechanism of action that could mitigate the long-term concerns associated with profound bone turnover suppression. Its failure to clear the final safety hurdle left this significant gap in the osteoporosis treatment armamentarium unfilled.

Table 5: Comparative Profile of Odanacatib vs. Major Osteoporosis Therapies

Feature	Odanacatib	Alendronate (Bisphosphonate)	Denosumab (RANKL Inhibitor)	Teriparatide (Anabolic Agent)
Drug Class	Cathepsin K Inhibitor	Bisphosphonate	Monoclonal Antibody	Parathyroid Hormone Analogue
Mechanism of Action	Antiresorptive: Inhibits CatK enzymatic activity, preserving osteoclast viability ("formation-sparing") 16	Antiresorptive: Induces osteoclast apoptosis, suppressing overall bone turnover 16	Antiresorptive: Inhibits osteoclast formation, function, and survival 12	Anabolic: Directly stimulates osteoblast activity to form new bone 46
Administration	Oral, once weekly 8	Oral, once weekly or daily (with strict dosing rules) 45	Subcutaneous injection, every 6 months 53	Subcutaneous injection, daily 45
Key Efficacy	High reduction in vertebral and hip fracture risk; progressive BMD gains 14	Moderate reduction in vertebral and hip fracture risk; moderate BMD gains 44	High reduction in vertebral and hip fracture risk; progressive BMD gains 44	Very high reduction in vertebral fracture risk; rapid and large lumbar spine BMD gains 44
Key Safety Concerns	Increased risk of stroke; morphea-like skin lesions; atypical femoral fractures (AFFs) 14	Atypical femoral fractures (AFFs); osteonecrosis of the jaw (ONJ); upper GI irritation 44	Atypical femoral fractures (AFFs); osteonecrosis of the jaw (ONJ); serious infections; rebound fractures on discontinuation 44	Hypercalcemia; dizziness; theoretical osteosarcoma risk (from rat studies) 45
Reversibility	High: Effects reverse within 1–2 years of discontinuation 8	Low: Prolonged effect due to incorporation into bone matrix 21	High: Effects reverse rapidly, requiring timely re-dosing to avoid rebound bone loss 54	High: Effects wane after discontinuation [N/A]

Conclusion and Future Implications for the Cathepsin K Inhibitor Class

9.1. Summary of Odanacatib's Trajectory

The story of Odanacatib is a powerful narrative of immense scientific promise met with an insurmountable clinical reality. It began with an elegant and rational drug design, targeting a key enzyme in bone resorption with a novel, formation-sparing mechanism that was theoretically superior to existing therapies. This promise was borne out through a rigorous clinical development program that delivered unequivocally strong efficacy data, demonstrating a potent ability to increase bone density and, most importantly, to prevent the debilitating fractures associated with osteoporosis. The drug's performance was so compelling that its pivotal Phase III trial was halted early for success, positioning Odanacatib on a trajectory to become a transformative, blockbuster therapy.

However, this trajectory was ultimately broken by the emergence of a critical, albeit low-frequency, safety signal. The meticulous collection and independent adjudication of long-term safety data revealed a statistically significant increase in the risk of stroke. For a medication intended for chronic, widespread use as a preventative measure, this adverse outcome created an unfavorable benefit-risk profile that was untenable for regulatory approval and clinical acceptance. The final decision to discontinue development, though disappointing, was a testament to the rigorous safety standards that govern modern medicine. Odanacatib will be remembered as a cautionary tale: a drug that succeeded spectacularly in its primary therapeutic goal but failed at the final, most critical hurdle of safety.

9.2. Lessons Learned and the Path Forward for Novel Osteoporosis Therapies

The downfall of Odanacatib offers several crucial lessons for the future development of therapies for chronic diseases. First, it underscores the absolute necessity of large, long-term, placebo-controlled safety studies. The stroke signal associated with Odanacatib was subtle and only became statistically clear after the accumulation of a large number of patient-years of exposure in the LOFT trial and its extension. Without such a robust dataset, this critical risk might have been missed, with potentially devastating consequences post-approval.

Second, the Odanacatib case leaves a profound and unresolved scientific question for the Cathepsin K inhibitor class. The mechanistic link between CatK inhibition and ischemic stroke remains a mystery, particularly as preclinical evidence pointed, if anything, toward a potential cardiovascular benefit. It is unknown whether this risk was an off-target effect specific to the Odanacatib molecule or an on-target, class-wide effect of inhibiting CatK in extra-skeletal tissues, such as the vasculature or atherosclerotic plaques. Answering this question is a prerequisite for any future attempts to develop drugs in this class. Any new CatK inhibitor would need to be built on a different chemical scaffold and would face intense regulatory scrutiny of its cardiovascular safety profile from the earliest stages of development.

Finally, the failure of Odanacatib highlights the high bar for innovation in the osteoporosis field. While its unique mechanism and impressive efficacy were highly attractive, the episode has reinforced that for a new drug to succeed in this space, it must not only demonstrate superior or differentiated efficacy but must do so with an impeccable safety profile that is, at a minimum, non-inferior to the established and often genericized standards of care. The search for the ideal osteoporosis therapy—one that combines potent anabolic and antiresorptive effects with convenience and long-term safety—continues, shaped by the hard-won lessons from the rise and fall of Odanacatib.

Works cited

1. Odanacatib: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 7, 2025, https://go.drugbank.com/drugs/DB06670
2. Odanacatib - Wikipedia, accessed September 7, 2025, https://en.wikipedia.org/wiki/Odanacatib
3. Odanacatib | C25H27F4N3O3S | CID 10152654 - PubChem, accessed September 7, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Odanacatib
4. ODANACATIB - precisionFDA, accessed September 7, 2025, https://precision.fda.gov/ginas/app/ui/substances/a860ab6f-f883-4f0c-923e-3b1ad5f50dcd
5. Odanacatib (MK-0822, CAS Number: 603139-19-1) | Cayman Chemical, accessed September 7, 2025, https://www.caymanchem.com/product/21466/odanacatib
6. Odanacatib (MK-0822)|Cathepsin K,potent and selective - APExBIO, accessed September 7, 2025, https://www.apexbt.com/odanacatib-mk-0822.html
7. Odanacatib | CAS 603139-19-1 | SCBT - Santa Cruz Biotechnology, accessed September 7, 2025, https://www.scbt.com/p/odanacatib-603139-19-1
8. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial - PMC, accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4312384/
9. Merck decision to drop odanacatib lifts UCB/Amgen - PMLiVE, accessed September 7, 2025, https://pmlive.com/pharma_news/merck_decision_to_drop_odanacatib_lifts_ucbamgen_1121642/
10. Odanacatib Efficacy Stays Strong, Side Effects Give Pause - Medscape, accessed September 7, 2025, https://www.medscape.com/viewarticle/832009
11. Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women - ResearchGate, accessed September 7, 2025, https://www.researchgate.net/publication/276109000_Odanacatib_a_review_of_its_potential_in_the_management_of_osteoporosis_in_postmenopausal_women
12. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bon, accessed September 7, 2025, https://www.panoramaortho.com/wp-content/uploads/2017/06/Odanacatib-a-cathepsin-K-inhibitor-for-the-treatment-of-osteoporosis-and-other-skeletal-disorders-associated-with-excessive-bone-remodeling.pdf
13. Update on Phase III Trial for Odanacatib, Merck's Investigational Cat-K Inhibitor for Osteoporosis, accessed September 7, 2025, https://www.merck.com/news/update-on-phase-iii-trial-for-odanacatib-mercks-investigational-cat-k-inhibitor-for-osteoporosis/
14. Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis, accessed September 7, 2025, https://www.merck.com/news/merck-announces-data-from-pivotal-phase-3-fracture-outcomes-study-for-odanacatib-an-investigational-oral-once-weekly-treatment-for-osteoporosis/
15. Clinical and translational pharmacology of the cathepsin K inhibitor ..., accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6533439/
16. Cathepsin K Inhibitor: Unique Mechanism of Action--Osteoporosis--Transcript, accessed September 7, 2025, https://www.medscape.org/viewarticle/588253
17. Odanacatib | CAS#603139-19-1 | Cathepsin K inhibitor - MedKoo Biosciences, accessed September 7, 2025, https://www.medkoo.com/products/4706
18. Odanacatib (MK-0822) | Cathepsin K Inhibitor - MedchemExpress.com, accessed September 7, 2025, https://www.medchemexpress.com/Odanacatib.html
19. Odanacatib for the treatment of osteoporosis - PubMed, accessed September 7, 2025, https://pubmed.ncbi.nlm.nih.gov/26149759/
20. Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women - PMC - PubMed Central, accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4426100/
21. Effects of Odanacatib on BMD and Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate: A Randomized Placebo-Controlled Trial - Oxford Academic, accessed September 7, 2025, https://academic.oup.com/jcem/article/98/12/4727/2834320
22. Odanacatib: a possible new therapeutic option for the treatment of osteoporosis - Open Access Journals, accessed September 7, 2025, https://www.openaccessjournals.com/articles/odanacatib-a-possible-new-therapeutic-option-for-the-treatment-of-osteoporosis.pdf
23. New Data on Odanacatib, Merck's Phase III Investigational Cat-K Inhibitor for Osteoporosis, Presented at the Annual Meeting of The American Society for Bone and Mineral Research, accessed September 7, 2025, https://www.merck.com/news/new-data-on-odanacatib-mercks-phase-iii-investigational-cat-k-inhibitor-for-osteoporosis-presented-at-the-annual-meeting-of-the-american-society-for-bone-and-mineral-research/
24. Potential role of odanacatib in the treatment of osteoporosis | CIA - Dove Medical Press, accessed September 7, 2025, https://www.dovepress.com/potential-role-of-odanacatib-in-the-treatment-of-osteoporosis-peer-reviewed-fulltext-article-CIA
25. Biologic Osteoporosis Drugs Denosumab and Odanacatib Show Promise in Clinical Trials - NATAP, accessed September 7, 2025, https://www.natap.org/2008/HIV/092208_05.htm
26. Novel Bone Drug (odanacatib, cathepsin K inhibitor) Found Safe After Four Years - NATAP, accessed September 7, 2025, https://natap.org/2010/HIV/102210_06.htm
27. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics, accessed September 7, 2025, http://jupiter.chem.uoa.gr/thanost/papers/papers8/BrJClinPharmacol_75(2012)1240.pdf
28. Population Pharmacokinetic Analysis of the Cathepsin K Inhibitor Odanacatib: Insights Into Intrinsic and Extrinsic Factor Effects on Exposure in Postmenopausal and Elderly Women | Request PDF - ResearchGate, accessed September 7, 2025, https://www.researchgate.net/publication/340737797_Population_Pharmacokinetic_Analysis_of_the_Cathepsin_K_Inhibitor_Odanacatib_Insights_Into_Intrinsic_and_Extrinsic_Factor_Effects_on_Exposure_in_Postmenopausal_and_Elderly_Women
29. Disposition and Metabolism of the Cathepsin K Inhibitor Odanacatib in Humans, accessed September 7, 2025, https://www.semanticscholar.org/paper/Disposition-and-Metabolism-of-the-Cathepsin-K-in-Kassahun-Mcintosh/c479ed6531c82156e03674b43d19d3383aeea761
30. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics - SciSpace, accessed September 7, 2025, https://scispace.com/pdf/odanacatib-a-selective-cathepsin-k-inhibitor-to-treat-3dlmbabge4.pdf
31. Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study - PubMed, accessed September 7, 2025, https://pubmed.ncbi.nlm.nih.gov/23716037/
32. Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women - ResearchGate, accessed September 7, 2025, https://www.researchgate.net/publication/47430064_Odanacatib_a_New_Drug_for_the_Treatment_of_Osteoporosis_Review_of_the_Results_in_Postmenopausal_Women
33. Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women - PMC, accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2951121/
34. Merck Researchers Present BMD Data from a Phase II Study of Odanacatib, Merck's Investigational Cat-K Inhibitor for Post-Menopausal Osteoporosis, accessed September 7, 2025, https://www.merck.com/news/merck-researchers-present-bmd-data-from-a-phase-ii-study-of-odanacatib-mercks-investigational-cat-k-inhibitor-for-post-menopausal-osteoporosis/
35. Merck Discontinues Development of Osteoporosis Drug Due to Stroke Risk, accessed September 7, 2025, https://www.pharmacytimes.com/view/merck-discontinues-development-of-osteoporosis-drug-due-to-stroke-risk
36. Odanacatib Efficacy and Safety in Postmenopausal Women with Osteoporosis: 5-Year Data from the Extension of the Phase 3 Long-Term Odanacatib Fracture Trial - ACR Meeting Abstracts, accessed September 7, 2025, https://acrabstracts.org/abstract/odanacatib-efficacy-and-safety-in-postmenopausal-women-with-osteoporosis-5-year-data-from-the-extension-of-the-phase-3-long-term-odanacatib-fracture-trial/
37. Odanacatib Reduces Fracture Risk in Postmenopausal Women With Osteoporosis, accessed September 7, 2025, https://firstwordpharma.com/story/2529025
38. Odanacatib reduced fractures but upped stroke risk - MDEdge, accessed September 7, 2025, https://www.mdedge.com/obgyn/article/115967/menopause/odanacatib-reduced-fractures-upped-stroke-risk
39. Odanacatib reduces fracture risk but increases risk of stroke: Lancet, accessed September 7, 2025, https://speciality.medicaldialogues.in/odanacatib-reduces-fracture-risk-but-increases-stroke-risk-in-postmenopausal-women-lancet
40. Merck Provides Update on Odanacatib Development Program, accessed September 7, 2025, https://www.merck.com/news/merck-provides-update-on-odanacatib-development-program/
41. Merck & Co. ends development of osteoporosis drug odanacatib due to increased stroke risk, accessed September 7, 2025, https://firstwordpharma.com/story/4195946
42. Bone Loss Drug Passes Trial; Side Effects Linger - HealthManagement.org, accessed September 7, 2025, https://healthmanagement.org/c/pharmacy/News/bone-loss-drug-passes-trial-side-effects-linger
43. Newer Therapies for Osteoporosis: A Systematic Review - JAPI, accessed September 7, 2025, https://www.japi.org/article/japi-73-8-67
44. Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures: An Updated Systematic Review: Annals of Internal Medicine - ACP Journals, accessed September 7, 2025, https://www.acpjournals.org/doi/10.7326/M14-0317
45. Alendronate vs Teriparatide Comparison - Drugs.com, accessed September 7, 2025, https://www.drugs.com/compare/alendronate-vs-teriparatide
46. Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal os - European Review for Medical and Pharmacological Sciences, accessed September 7, 2025, https://www.europeanreview.org/wp/wp-content/uploads/8253-8268.pdf
47. Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis - Frontiers, accessed September 7, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1431676/full
48. Review of Current Real-World Experience with Teriparatide as Treatment of Osteoporosis in Different Patient Groups - MDPI, accessed September 7, 2025, https://www.mdpi.com/2077-0383/10/7/1403
49. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use - PMC, accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6785688/
50. (PDF) Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study - ResearchGate, accessed September 7, 2025, https://www.researchgate.net/publication/360457790_Comparative_effectiveness_and_cardiovascular_safety_of_abaloparatide_and_teriparatide_in_postmenopausal_women_new_to_anabolic_therapy_A_US_administrative_claims_database_study
51. Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial - PMC - PubMed Central, accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7500469/
52. Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study, accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9499892/
53. Prolia vs Teriparatide Comparison - Drugs.com, accessed September 7, 2025, https://www.drugs.com/compare/prolia-vs-teriparatide
54. Denosumab for the Treatment of Osteoporosis - PMC, accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4480604/
55. Efficacy and Safety of Denosumab in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and a Meta-analysis - ResearchGate, accessed September 7, 2025, https://www.researchgate.net/publication/26301632_Efficacy_and_Safety_of_Denosumab_in_Postmenopausal_Women_with_Osteopenia_or_Osteoporosis_A_Systematic_Review_and_a_Meta-analysis